JP2022093718A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022093718A5 JP2022093718A5 JP2022076767A JP2022076767A JP2022093718A5 JP 2022093718 A5 JP2022093718 A5 JP 2022093718A5 JP 2022076767 A JP2022076767 A JP 2022076767A JP 2022076767 A JP2022076767 A JP 2022076767A JP 2022093718 A5 JP2022093718 A5 JP 2022093718A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 37
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 150000003573 thiols Chemical class 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 claims description 2
- 102000009658 Peptidylprolyl Isomerase Human genes 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- -1 substituted Chemical class 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 101000827313 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 claims 1
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims 1
- 102100027914 Peptidyl-prolyl cis-trans isomerase FKBP1B Human genes 0.000 claims 1
- 102100023846 Peptidyl-prolyl cis-trans isomerase FKBP3 Human genes 0.000 claims 1
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 claims 1
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 108010029517 tacrolimus binding protein 1B Proteins 0.000 claims 1
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 14
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 13
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 13
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 11
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 8
- 239000003814 drug Substances 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002678 macrocyclic compounds Chemical class 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000005591 NIMA-Interacting Peptidylprolyl Isomerase Human genes 0.000 description 1
- 108010059419 NIMA-Interacting Peptidylprolyl Isomerase Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 1
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024127925A JP2024149655A (ja) | 2015-01-09 | 2024-08-02 | 協同的結合に関与する化合物及びその使用方法 |
| JP2025188241A JP2026015411A (ja) | 2015-01-09 | 2025-11-07 | 協同的結合に関与する化合物及びその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101925P | 2015-01-09 | 2015-01-09 | |
| US62/101,925 | 2015-01-09 | ||
| JP2019211918A JP2020063256A (ja) | 2015-01-09 | 2019-11-25 | 協同的結合に関与する化合物及びその使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019211918A Division JP2020063256A (ja) | 2015-01-09 | 2019-11-25 | 協同的結合に関与する化合物及びその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024127925A Division JP2024149655A (ja) | 2015-01-09 | 2024-08-02 | 協同的結合に関与する化合物及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022093718A JP2022093718A (ja) | 2022-06-23 |
| JP2022093718A5 true JP2022093718A5 (enExample) | 2022-08-09 |
Family
ID=56356469
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555427A Pending JP2018507251A (ja) | 2015-01-09 | 2016-01-08 | 協同的結合に関与する化合物及びその使用方法 |
| JP2019211918A Pending JP2020063256A (ja) | 2015-01-09 | 2019-11-25 | 協同的結合に関与する化合物及びその使用方法 |
| JP2022076767A Pending JP2022093718A (ja) | 2015-01-09 | 2022-05-06 | 協同的結合に関与する化合物及びその使用方法 |
| JP2024127925A Pending JP2024149655A (ja) | 2015-01-09 | 2024-08-02 | 協同的結合に関与する化合物及びその使用方法 |
| JP2025188241A Pending JP2026015411A (ja) | 2015-01-09 | 2025-11-07 | 協同的結合に関与する化合物及びその使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555427A Pending JP2018507251A (ja) | 2015-01-09 | 2016-01-08 | 協同的結合に関与する化合物及びその使用方法 |
| JP2019211918A Pending JP2020063256A (ja) | 2015-01-09 | 2019-11-25 | 協同的結合に関与する化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024127925A Pending JP2024149655A (ja) | 2015-01-09 | 2024-08-02 | 協同的結合に関与する化合物及びその使用方法 |
| JP2025188241A Pending JP2026015411A (ja) | 2015-01-09 | 2025-11-07 | 協同的結合に関与する化合物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10039839B2 (enExample) |
| EP (3) | EP3247377A4 (enExample) |
| JP (5) | JP2018507251A (enExample) |
| AR (1) | AR105755A1 (enExample) |
| MA (1) | MA41381A (enExample) |
| TW (1) | TW201629069A (enExample) |
| WO (1) | WO2016112279A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| WO2016112295A1 (en) | 2015-01-09 | 2016-07-14 | Warp Drive Bio, Inc. | Compounds that participate in cooperative binding and uses thereof |
| CA3000822A1 (en) | 2015-10-01 | 2017-04-06 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CA3020594A1 (en) | 2016-04-12 | 2017-10-19 | Warp Drive Bio, Inc. | Compositions and methods for the production of compounds |
| US20200199102A1 (en) * | 2017-04-05 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| WO2018187423A1 (en) * | 2017-04-05 | 2018-10-11 | Warp Drive Bio, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| CN110730822B (zh) * | 2017-04-18 | 2024-03-08 | X-化学有限公司 | 鉴定化合物的方法 |
| CN121471132A (zh) | 2019-11-04 | 2026-02-06 | 锐新医药公司 | Ras抑制剂 |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| WO2021091956A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| IL308195A (en) | 2021-05-05 | 2024-01-01 | Revolution Medicines Inc | RAS inhibitors for cancer treatment |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN116083290B (zh) * | 2022-11-21 | 2024-06-14 | 陕西省微生物研究所 | 一种铅锌和/或抗生素和/或抗性基因污染土壤修复的复合微生物菌剂及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2089723T3 (es) | 1992-03-27 | 1996-10-01 | American Home Prod | 29-demetoxirapamicina para inducir la inmunodepresion. |
| WO1995008548A1 (en) | 1993-09-20 | 1995-03-30 | The Leland Stanford Junior University | Recombinant production of novel polyketides |
| IL112873A (en) | 1994-03-08 | 2005-03-20 | Wyeth Corp | Rapamycin-fkbp12 binding proteins, their isolation and their use |
| GB9410142D0 (en) | 1994-05-20 | 1994-07-06 | Univ Warwick | Carbapenems |
| GB9524630D0 (en) * | 1994-12-24 | 1996-01-31 | Zeneca Ltd | Chemical compounds |
| US5624677A (en) | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US6902913B2 (en) | 1997-04-30 | 2005-06-07 | Kosan Biosciences, Inc. | Recombinant narbonolide polyketide synthase |
| US6153383A (en) | 1997-12-09 | 2000-11-28 | Verdine; Gregory L. | Synthetic transcriptional modulators and uses thereof |
| US6372712B1 (en) | 1998-05-22 | 2002-04-16 | The Board Of Trustees Of The Leland Stanford Jr. University | Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand |
| GB9927191D0 (en) | 1999-11-17 | 2000-01-12 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| US20070203168A1 (en) * | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
| WO2010031185A1 (en) | 2008-09-19 | 2010-03-25 | Protox Therapeutics Inc. | Treating cancer stem cells using targeted cargo proteins |
| JP5789190B2 (ja) | 2008-09-24 | 2015-10-07 | シャンハイ インスティテュート オブ オーガニック ケミストリー，チャイニーズ アカデミー オブ サイエンシズ | 新規の遺伝子クラスター |
| RU2492181C2 (ru) | 2009-01-30 | 2013-09-10 | Энанта Фармасьютикалс, Инк. | Аналоги циклоспорина для предупреждения или лечения инфекции гепатита с |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| EP2456777A2 (en) | 2009-07-24 | 2012-05-30 | Université Henri Poincaré - Nancy 1 | Stambomycin and derivatives, their production and their use as drugs |
| CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP5174971B2 (ja) | 2009-10-22 | 2013-04-03 | ペプチドリーム株式会社 | ペプチド翻訳合成におけるｒａｐｉｄディスプレイ法 |
| AU2011336727B2 (en) | 2010-11-30 | 2016-11-03 | The Johns Hopkins University | Hybrid cyclic libraries and screens thereof |
| US9428845B1 (en) | 2010-12-28 | 2016-08-30 | Warp Drive Bio, Inc. | Identifying new therapeutic agents |
| US9260484B2 (en) * | 2011-06-15 | 2016-02-16 | Ohio State Innovation Foundation | Small molecule composite surfaces as inhibitors of protein-protein interactions |
| EP2806274A1 (en) | 2013-05-24 | 2014-11-26 | AIT Austrian Institute of Technology GmbH | Lung cancer diagnostic method and means |
| CN106255882A (zh) | 2014-03-03 | 2016-12-21 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 用于检测铜绿假单胞菌的方法和装置 |
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| IL317393A (en) * | 2018-12-21 | 2025-02-01 | Revolution Medicines Inc | Compounds that participate in covalent bonds and their uses |
-
2016
- 2016-01-05 TW TW105100137A patent/TW201629069A/zh unknown
- 2016-01-07 MA MA041381A patent/MA41381A/fr unknown
- 2016-01-08 US US14/991,403 patent/US10039839B2/en active Active
- 2016-01-08 EP EP16735470.3A patent/EP3247377A4/en not_active Withdrawn
- 2016-01-08 EP EP24222224.8A patent/EP4545521A3/en active Pending
- 2016-01-08 EP EP20176025.3A patent/EP3757109A1/en not_active Withdrawn
- 2016-01-08 WO PCT/US2016/012631 patent/WO2016112279A1/en not_active Ceased
- 2016-01-08 JP JP2017555427A patent/JP2018507251A/ja active Pending
- 2016-01-08 AR ARP160100047A patent/AR105755A1/es unknown
-
2018
- 2018-07-16 US US16/036,141 patent/US20180318434A1/en not_active Abandoned
-
2019
- 2019-11-25 JP JP2019211918A patent/JP2020063256A/ja active Pending
-
2021
- 2021-06-10 US US17/344,566 patent/US20220143202A1/en not_active Abandoned
-
2022
- 2022-05-06 JP JP2022076767A patent/JP2022093718A/ja active Pending
-
2024
- 2024-08-02 JP JP2024127925A patent/JP2024149655A/ja active Pending
- 2024-09-27 US US18/899,370 patent/US20250121077A1/en active Pending
-
2025
- 2025-11-07 JP JP2025188241A patent/JP2026015411A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102820455B1 (ko) | Shp2 활성 억제용 화합물의 제조 방법 | |
| CN105102451B (zh) | N-苯基-氨甲酰衍生物及其作为药物用于治疗乙型肝炎的用途 | |
| AU2015299055C1 (en) | Prodrugs comprising an aminoalkyl glycine linker | |
| JP2020513036A5 (enExample) | ||
| AU2022268781A1 (en) | Cyclic Compound having Selective Inhibitory Action on KRAS over HRAS and NRAS | |
| JP5372751B2 (ja) | Ａｚａ−ペプチドプロテアーゼ阻害剤 | |
| CA3201793A1 (en) | Macrocycles containing a 1,3,4-oxadiazole ring for use as modulators of cystic fibrosis transmembrane conductance regulator | |
| TW202128699A (zh) | 治療性化合物 | |
| CN115991708A (zh) | Hiv抑制剂化合物 | |
| CN111018857A (zh) | 靶向蛋白酶降解平台(ted) | |
| JP2003529609A (ja) | 核酸結合部分を含む荷電した化合物およびその利用法 | |
| AU2019355218B2 (en) | Monomer and multimeric anti-HBV agents | |
| JPH09500120A (ja) | 環式ヒドラジン化合物 | |
| CN101801965A (zh) | 作为细胞坏死抑制剂的吲哚化合物 | |
| JP2006507265A5 (enExample) | ||
| PL195368B1 (pl) | Kompozycja farmaceutyczna i zastosowanie związku sulfonoamidowego zawierającego grupę tetrahydrofuranylową | |
| WO2000032606A1 (en) | IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM | |
| TW200528440A (en) | 2-cyanopyrrolidinecarboxamide compound | |
| WO1998017625A1 (en) | Novel remedies for infectious diseases | |
| JP2018507251A (ja) | 協同的結合に関与する化合物及びその使用方法 | |
| TW552260B (en) | Endothelin antagonists | |
| JP2021503508A (ja) | 置換大環状インドール誘導体 | |
| KR20120125610A (ko) | 시클로스포린 유사체 | |
| Gleave et al. | Synthesis and antibacterial activity of [6, 5, 5] and [6, 6, 5] tricyclic fused oxazolidinones | |
| Ma et al. | Identification of benzothiazones containing a hexahydropyrrolo [3, 4-c] pyrrol moiety as antitubercular agents against MDR-MTB |